Literature DB >> 31564273

Serum Des-gamma-carboxy Prothrombin for Diagnosis of Adult Primary Cancer in Liver.

Youdi Li1, Jiu Chen1.   

Abstract

OBJECTIVE: To explore the diagnostic accuracy of serum des-gamma-carboxy prothrombin (DCP) in adult primary cancer in liver. STUDY
DESIGN: Descriptive study. PLACE AND DURATION OF STUDY: Department of Traditional Chinese Medicine, the First Affiliated Hospital, College of Medicine, Zhejing University, Hangzhou, China, from June 2016 to March 2018.
METHODOLOGY: A retrospective study of 1,190 cases was undertaken and all the participants were divided into Group 1 (non-cancer patients) and Group 2 (primary cancer in liver patients). The records of DCP and alpha fetoprotein (AFP) levels were extracted and compared between Group 1 and Group 2. The sensitivity, specificity, and cutoff point of DCP in Group 2 and its different histological types were calculated. The receiver operating characteristic (ROC) curves were obtained, and the areas under the receiver operating characteristic curve (AUROC) were calculated and compared in different histological types.
RESULTS: The DCP and AFP levels in Group 2 were markedly higher than Group 1 (p <0.001). For primary cancer in liver, the sensitivity, specificity, cutoff value, and AUROC of DCP were 64.2%, 91%, 56.5 mAU/mL, and 0.807 (95% CI: 0.783- 0.832), respectively. For hepatocellular carcinoma (HCC), the sensitivity, specificity, cutoff value, and AUROC of DCP were 69.3%, 92.2%,60.5mAU/mL, and 0.846 (95% CI: 0.817-0.875), respectively. For intrahepatic cholangiocarcinoma (ICC), the sensitivity, specificity, cutoff value, and AUROC of DCP were 13.6%, 93.2%, 76.5 mAU/mL, and 0.512 (95% CI: 0.439- 0.586), respectively. For combined hepatocellular-cholangiocarcinoma (cHCC-CC), the sensitivity, specificity, cutoff value, and AUROC of DCP were 66.7%, 81.5%, 40.5 mAU/mL, and 0.737 (95% CI: 0.585-0.888), respectively.
CONCLUSION: DCP could be considered not only for surveillance and diagnosis of primary cancer in liver, but also for differential diagnosis of its different histological types.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31564273     DOI: 10.29271/jcpsp.2019.10.972

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  5 in total

1.  Plasma Small Extracellular Vesicles Derived miR-21-5p and miR-92a-3p as Potential Biomarkers for Hepatocellular Carcinoma Screening.

Authors:  Andrei Sorop; Razvan Iacob; Speranta Iacob; Diana Constantinescu; Leona Chitoiu; Tudor Emanuel Fertig; Anca Dinischiotu; Mihaela Chivu-Economescu; Nicolae Bacalbasa; Lorand Savu; Liliana Gheorghe; Simona Dima; Irinel Popescu
Journal:  Front Genet       Date:  2020-07-23       Impact factor: 4.599

2.  Validation of the GALAD Model and Establishment of GAAP Model for Diagnosis of Hepatocellular Carcinoma in Chinese Patients.

Authors:  Miaoxia Liu; Ruihong Wu; Xu Liu; Hongqin Xu; Xiumei Chi; Xiaomei Wang; Mengru Zhan; Bao Wang; Fei Peng; Xiuzhu Gao; Ying Shi; Xiaoyu Wen; Yali Ji; Qinglong Jin; Junqi Niu
Journal:  J Hepatocell Carcinoma       Date:  2020-10-23

3.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

4.  Dynamics of Health Technology Diffusion in the Integrated Care System (DHTDICS): A Development and Validation Study in China.

Authors:  Qingwen Deng; Junhong Lu; Zhichao Zeng; Yuhang Zheng; Wenbin Liu
Journal:  Risk Manag Healthc Policy       Date:  2021-01-27

5.  The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China.

Authors:  Jun Ji; Lijuan Liu; Feifei Jiang; Xue Wen; Yu Zhang; Shengcong Li; Jinli Lou; Ying Wang; Ning Liu; Qiuyan Guo; Yongmei Jia; Chunfang Gao
Journal:  J Clin Lab Anal       Date:  2021-09-30       Impact factor: 2.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.